MedTrace Logo

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

NCT06011109 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-02

No results posted yet for this study

Summary

The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are:

* Progression-free and overall survival of patients receiving this combination;
* Quality of Life (QOL); and
* Tumor response on imaging

The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth.

The participants will continue to receive Bevacizumab as standard of care.

Conditions

Interventions

DRUG

APG-157

The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.

Sponsors & Collaborators

  • Aveta Biomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicole Shonka, MD · University of Nebraska

  • Joon Uhm, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2025-12-31
Completion
2026-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011109 on ClinicalTrials.gov